James V. Tricoli, PhD

Articles by James V. Tricoli, PhD

Prostate Cancer Risk Assessment Program

ByDeborah Watkins Bruner, RN, MSN,Agnes Baffoe-bonnie, MD, PhD,Suzanne Miller, PhD,Michael Diefenbach, PhD,James V. Tricoli, PhD,Mary Daly, MD, PhD,Wayne Pinover, DO,Sherry Campbell Grumet, MA,Eric Ross, PhD,Andrew Balshem, MD,Paul F. Engstrom, MD,Gerald E. Hanks, MD,Iila Mirchandani, MD

March 1st 1999

Prostate cancer is the most common form of cancer (except skin cancer) in men. Several factors have been associated with an increased risk for prostate cancer, including age, ethnicity, family history, lifestyle, and

Latest Updated Articles

Prostate Cancer Risk Assessment Program
March 1st 1999

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Achieving a “Functional Cure” With Multiple Myeloma Therapy

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)